期刊文献+

E2F3在喉鳞状细胞癌中的表达及临床意义

The expression and clinical significance of E2F3 in laryngeal squamous cell carcinoma
下载PDF
导出
摘要 目的:探讨喉鳞癌中E2F3的表达与临床意义,为喉鳞癌的诊断、评估及治疗寻找辅助生物学指标。方法:采用免疫组化方法检测喉鳞癌组织及癌旁正常切缘组织中E2F3表达,结合喉鳞癌各临床参数,用SPSS16.0软件包进行统计分析E2F3表达情况与喉鳞癌各临床特征之间的关系。结果:E2F3在喉鳞癌与癌旁正常切缘中的阳性表达率分别为90.44%(123/136)和27.85%(22/79),差异具有显著统计学意义(P<0.001);E2F3高表达与喉鳞癌患者年龄、临床分期及分型均相关(P<0.05)。结论:E2F3核表达可能参与喉鳞癌发生发展过程;E2F3浆表达可能贯穿于喉鳞癌发生的整体过程。 Objective:To study the expression and clinical significance of E2F3 in laryngeal squamous cell carcinoma.Methods:Immunohistochemical staining was used to detect the expression of E2F3 protein in 136 laryngeal squamous cell carcinoma tissues and 79 adjacent normal tissues.The correlations of E2F3 with clinicopathological factors were analyzed.Results:The positive rates of E2F3 in the adjacent normal tissues and laryngeal squamous cell carcinoma tissues were 90.44%(123/136) and 27.85%(22/79) respectively.The expression of E2F3 in laryngeal squamous cell carcinoma was higher than that in normal mucosa(P0.01).The expression of E2F3 in laryngeal squamous cell carcinoma tissues was correlated with the clinical stage,age,type,and differentiation degree(P0.05).And it was not correlated with the T stage,lymph node metastasis,smoking and gender(P0.05).In addition,very high level expression of nuclear E2F3 was found in almost all subglottic laryngeal squamous cell carcinomas.Conclusion:The expression of E2F3 was highly up-regulated in laryngeal squamous cell carcinoma tissue.It had a relationship with the clinical stage,age,type,and differentiation degree.It may have an important significance on predicting the invasion of laryngeal squamous cell carcinomas,and may permit the laryngeal tumorigenesis and progression.
出处 《现代肿瘤医学》 CAS 2012年第5期924-927,共4页 Journal of Modern Oncology
基金 国家自然科学基金(项目编号:81172584)
关键词 E2F3 喉肿瘤 鳞状细胞癌 免疫组织化学 E2F3 laryngeal tumor squamous cell carcinoma immunohistochemical
  • 相关文献

参考文献12

  • 1Humbert PO,Verona R,Trimarchi JM,et al.E2f3 is critical fornormal cellular proliferation[J].Genes Dev,2000,14(6):690-703.
  • 2Johnson DG,Degregori J.Putting the oncogenic and tumor sup-pressive activities of E2F into context[J].Curr Mol Med,2006,6(7):731-738.
  • 3Kovesdi I,Reichel R,Nevins JR.Identification of a cellular tran-scription factorinvolved in ElA trans-activation[J].Cell,1986,45(2):219-228.
  • 4Parisi T,Yuan TL,Faust AM,et al.Selective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chim-eric tissues[J].Mol Cell Biol,2007,27(6):2283-2293.
  • 5Ginsberg D.E2F3-a novel repressor of the ARF/p53 pathway[J].Dev Cell,2004,6(6):742-743.
  • 6Foster CS,Falconer A,Dodson AR,et al.Transcription factorE2F3 overexpressed in prostate cancer in dependently predictsclinical outcome[J].Oncogene,2004,23(35):5871-5879.
  • 7DeGregori J,Johnson DG.Distinct and overlapping roles for E2Ffamily members in transcription,proliferation and apoptosis[J].Curr Mol Med,2006,6(7):739-748.
  • 8Hurst CD,Tomlinson DC,Williams SV,et al.Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are ob-ligate events in bladder tumours with 6p22 amplification[J].Oncogene,2008,27(19):2716-2727.
  • 9Kort EJ,Farber L,Tretiakova M,et al.The E2F3-Oncomir 1axis is activated in Wilms tumor[J].Cancer Res,2008,68(11):4034-4038.
  • 10Cunningham JM,Vierkant RA,Sellers TA,et al.Cell cyclegenes and ovarian cancer susceptibility:a tagSNP analysis[J].Br J Cancer,2009,101(8):1461-1468.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部